Compare DRIO & XBIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DRIO | XBIT |
|---|---|---|
| Founded | 2011 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Pharmaceuticals and Biotechnology |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 84.1M | 73.2M |
| IPO Year | 2013 | 2015 |
| Metric | DRIO | XBIT |
|---|---|---|
| Price | $11.28 | $2.37 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $50.00 | N/A |
| AVG Volume (30 Days) | 19.1K | ★ 35.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 9.05 | N/A |
| Revenue | ★ $7,394,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $16.15 | N/A |
| P/E Ratio | $1.25 | ★ N/A |
| Revenue Growth | ★ 43.02 | N/A |
| 52 Week Low | $0.38 | $2.09 |
| 52 Week High | $17.74 | $3.62 |
| Indicator | DRIO | XBIT |
|---|---|---|
| Relative Strength Index (RSI) | 51.22 | 43.99 |
| Support Level | $9.30 | $2.32 |
| Resistance Level | $11.40 | $2.69 |
| Average True Range (ATR) | 0.70 | 0.10 |
| MACD | 0.12 | -0.01 |
| Stochastic Oscillator | 64.02 | 30.00 |
DarioHealth Corp is a digital therapeutics (DTx) company delivering personalized evidence-based interventions that are driven by precision data analytics, software, and personalized coaching. Its cross-functional team operates at the intersection of life sciences, behavioral science, and software technology to deliver seamlessly integrated and engaging digital therapeutics interventions. Also platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health.
XBiotech Inc is a United States-based clinical-stage biopharmaceutical company. The company is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing Anti-inflammatory therapeutic antibodies as a treatment for cancer. Geographically, all of its operations are in the United States.